9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Estimated reading time: < 1 min

Condition: Appendix Adenocarcinoma

Estimated Enrollment: 160

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Objective response,  Progression free survival,  Duration of response, Overall survival

Interventions: Atezolizumab, Bevacizumab

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 31, 2021

Completion Date: March 31, 2021

Last  Posted Date: June 13, 2019

Location: M D Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT03074513

Was this article helpful?
Dislike 0